Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours

Eleonora Vitali; Valeria Cambiaghi; Alessandro Zerbi; Carlo Carnaghi; Piergiuseppe Colombo; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea G. Lania

doi:10.1530/ERC-15-0358

Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours

Eleonora Vitali, Valeria Cambiaghi, Alessandro Zerbi, Carlo Carnaghi, Piergiuseppe Colombo, Erika Peverelli, Anna Spada, Giovanna Mantovani, Andrea G. Lania

Research output: Contribution to journal › Article › peer-review

Abstract

Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P

Original language	English
Pages (from-to)	181-190
Number of pages	10
Journal	Endocrine-Related Cancer
Volume	23
Issue number	3
DOIs	https://doi.org/10.1530/ERC-15-0358
Publication status	Published - Mar 1 2016

Keywords

Filamin A
Neuroendocrine tumours
Somatostatin
Somatostatin receptor type 2

ASJC Scopus subject areas

Endocrinology
Oncology
Cancer Research
Endocrinology, Diabetes and Metabolism

Access to Document

10.1530/ERC-15-0358

Fingerprint Dive into the research topics of 'Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this

Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours. / Vitali, Eleonora; Cambiaghi, Valeria; Zerbi, Alessandro ; Carnaghi, Carlo ; Colombo, Piergiuseppe ; Peverelli, Erika; Spada, Anna; Mantovani, Giovanna ; Lania, Andrea G.

In: Endocrine-Related Cancer, Vol. 23, No. 3, 01.03.2016, p. 181-190.

Research output: Contribution to journal › Article › peer-review

@article{fdef7823964f4de7b7ff5d915bc99413,

title = "Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours",

abstract = "Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P",

keywords = "Filamin A, Neuroendocrine tumours, Somatostatin, Somatostatin receptor type 2",

author = "Eleonora Vitali and Valeria Cambiaghi and Alessandro Zerbi and Carlo Carnaghi and Piergiuseppe Colombo and Erika Peverelli and Anna Spada and Giovanna Mantovani and Lania, {Andrea G.}",

year = "2016",

month = mar,

day = "1",

doi = "10.1530/ERC-15-0358",

language = "English",

volume = "23",

pages = "181--190",

journal = "Endocrine-Related Cancer",

issn = "1351-0088",

publisher = "BioScientifica Ltd.",

number = "3",

}

TY - JOUR

T1 - Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours

AU - Vitali, Eleonora

AU - Cambiaghi, Valeria

AU - Zerbi, Alessandro

AU - Carnaghi, Carlo

AU - Colombo, Piergiuseppe

AU - Peverelli, Erika

AU - Spada, Anna

AU - Mantovani, Giovanna

AU - Lania, Andrea G.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P

AB - Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P

KW - Filamin A

KW - Neuroendocrine tumours

KW - Somatostatin

KW - Somatostatin receptor type 2

UR - http://www.scopus.com/inward/record.url?scp=84963959675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963959675&partnerID=8YFLogxK

U2 - 10.1530/ERC-15-0358

DO - 10.1530/ERC-15-0358

M3 - Article

AN - SCOPUS:84963959675

VL - 23

SP - 181

EP - 190

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 3

ER -